Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Guerbet Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (76)
Cancellation by sponsor (36)
Prescription medicine registration (3)
Section 14, TGO91 consent (3)

Date

2026 (5)
2025 (32)
2023 (3)
2022 (2)
2021 (6)
2020 (8)
2019 (4)
2018 (8)
2017 (8)
2016 (7)
2015 (1)
2014 (1)
2013 (1)
2010 (3)
2003 (2)
2000 (5)
1999 (1)
1997 (2)
1995 (2)
1994 (12)
1993 (2)
1991 (3)

Search

Sponsor content

118 result(s) found, displaying 71 to 80

CONRAY-280 iotalamate meglumine 30g/50mL injection vial Cancelled under s30(1)(c)

11 January 2018

Cancellation by sponsor

Requested by Guerbet Australia Pty Ltd
Guerbet Australia Pty Ltd - Multi-purpose warming cabinet, stationary (222837)

28 April 2014

ARTG

Australian Register of Therapeutic Goods (ARTG) information for Guerbet Australia Pty Ltd - Multi-purpose warming cabinet, stationary.
OPTIMARK gadoversetamide 5.0mmol/10mL injection syringe Cancelled under s30(1)(c)

14 August 2017

Cancellation by sponsor

Requested by Guerbet Australia Pty Ltd
OPTIMARK gadoversetamide 5.0mmol/10mL injection vial Cancelled under s30(1)(c)

14 August 2017

Cancellation by sponsor

Requested by Guerbet Australia Pty Ltd
OPTIMARK gadoversetamide 7.5mmol/15mL injection vial Cancelled under s30(1)(c)

14 August 2017

Cancellation by sponsor

Requested by Guerbet Australia Pty Ltd
OPTIMARK gadoversetamide 10.0mmol/20mL injection vial Cancelled under s30(1)(c)

14 August 2017

Cancellation by sponsor

Requested by Guerbet Australia Pty Ltd
OPTIMARK gadoversetamide 7.5mmol/15mL injection syringe Cancelled under s30(1)(c)

14 August 2017

Cancellation by sponsor

Requested by Guerbet Australia Pty Ltd
OPTIMARK gadoversetamide 10.0mmol/20mL injection syringe Cancelled under s30(1)(c)

14 August 2017

Cancellation by sponsor

Requested by Guerbet Australia Pty Ltd
OPTIMARK gadoversetamide 15.0mmol/30mL injection syringe Cancelled under s30(1)(c)

14 August 2017

Cancellation by sponsor

Requested by Guerbet Australia Pty Ltd
OPTIMARK gadoversetamide 2.5mmol/5mL injection vial Cancelled under s30(1)(c)

14 August 2017

Cancellation by sponsor

Requested by Guerbet Australia Pty Ltd

Pages

First page
Previous page
…
Page 4
Page 5
Page 6
Page 7
Current page 8
Page 9
Page 10
Page 11
Page 12
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.